Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset
Cancer Research and Treatment · 2024
DOI: 10.4143/crt.2023.453 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Cancer Research and Treatment, 2024. Verfasst von Ki Hyeong Lee und 23 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheong…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Morpholines, Pyrazoles. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Yuhan Corporation, Tech Observer Asia Pacific Pte Ltd..
Abstract (Originalsprache)
Purpose
This subgroup analysis of the Korean subset of patients in the phase 3 LASER301 trial evaluated the efficacy and safety of lazertinib versus gefitinib as first-line therapy for epidermal growth factor receptor mutated (EGFRm) non–small cell lung cancer (NSCLC).Materials and Methods Patients with locally advanced or metastatic EGFRm NSCLC were randomized 1:1 to lazertinib (240 mg/day) or gefitinib (250 mg/day). The primary endpoint was investigator-assessed progression-free survival (PFS).
Results
In total, 172 Korean patients were enrolled (lazertinib, n=87; gefitinib, n=85). Baseline characteristics were balanced between the treatment groups. One-third of patients had brain metastases (BM) at baseline. Median PFS was 20.8 months (95% confidence interval [CI], 16.7 to 26.1) for lazertinib and 9.6 months (95% CI, 8.2 to 12.3) for gefitinib (hazard ratio [HR], 0.41; 95% CI, 0.28 to 0.60). This was supported by PFS analysis based on blinded independent central review. Significant PFS benefit with lazertinib was consistently observed across predefined subgroups, including patients with BM (HR, 0.28; 95% CI, 0.15 to 0.53) and those with L858R mutations (HR, 0.36; 95% CI, 0.20 to 0.63). Lazertinib safety data were consistent with its previously reported safety profile. Common adverse events (AEs) in both groups included rash, pruritus, and diarrhoea. Numerically fewer severe AEs and severe treatment–related AEs occurred with lazertinib than gefitinib.
Conclusion
Consistent with results for the overall LASER301 population, this analysis showed significant PFS benefit with lazertinib versus gefitinib with comparable safety in Korean patients with untreated EGFRm NSCLC, supporting lazertinib as a new potential treatment option for this patient population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology, Department of Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea.
- Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Center for Lung Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
- Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
Förderung
- Yuhan Corporation
- Tech Observer Asia Pacific Pte Ltd.
Zitieren
APA
Lee, K. H., Cho, B. C., Ahn, M. J., Lee, Y. G., Lee, Y., Lee, J. S., Kim, J. H., Min, Y. J., Lee, G. W., Lee, S. S., Lee, K. H., Ko, Y. H., Shim, B. Y., Kim, S. W., Shin, S. W., Choi, J. H., Kim, D. W., Cho, E. K., Park, K. U., …, & Kang, J. H. (2024). Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset. Cancer Research and Treatment. https://doi.org/10.4143/crt.2023.453
Vancouver
Lee KH, Cho BC, Ahn MJ, Lee YG, Lee Y, Lee JS, et al. Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset. Cancer Research and Treatment. 2024. doi:10.4143/crt.2023.453
BibTeX
@article{Lee2024,
author = {Lee, Ki Hyeong and Cho, Byoung Chul and Ahn, Myung-Ju and Lee, Yun-Gyoo and Lee, Youngjoo and Lee, Jong-Seok and Kim, Joo-Hang and Min, Young Joo and Lee, Gyeong-Won and Lee, Sung Sook and Lee, Kyung-Hee and Ko, Yoon Ho and Shim, Byoung Yong and Kim, Sang-We and Shin, Sang Won and Choi, Jin-Hyuk and Kim, Dong-Wan and Cho, Eun Kyung and Park, Keon Uk and Kim, Jin-Soo and Chun, Sang Hoon and Wang, Jangyoung and Choi, SeokYoung and Kang, Jin Hyoung},
title = {Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset},
journal = {Cancer Research and Treatment},
year = {2024},
doi = {10.4143/crt.2023.453}
}
EUVIMED